FDA Issues Complete Response Letter for Replimune's RP1 Oncolytic Immunotherapy, Delaying Melanoma Launch
Key Insights
The FDA issued a Complete Response Letter on July 22, 2025, for Replimune's RP1 oncolytic immunotherapy in advanced melanoma (search), delaying commercial launch and revenue generation.
Replimune's Q1 fiscal 2026 net loss widened 61% to $86.7 million as R&D expenses increased 34.6% to $57.8 million and administrative costs more than doubled to $32.6 million.
The company continues enrollment in the confirmatory IGNYTE-3 Phase 3 trial for RP1 in melanoma, aiming to enroll 400 patients globally to collect regulatory-requested data.
Replimune Group (search) reported a significant regulatory setback for its lead oncolytic immunotherapy RP1 after the U.S. Food and Drug Administration issued a Complete Response Letter on July 22, 2025, regarding the company's biologics license application for advanced melanoma (search) treatment. The regulatory feedback delays the anticipated commercial launch and revenue generation for the biotechnology company's flagship product.
The Complete Response Letter represents a major hurdle for Replimune's commercialization timeline, forcing the company to reassess its path to market approval. "We are committed to finding an expeditious path forward with the FDA," the company stated in response to the regulatory feedback.
Financial Impact and Operational Costs
Replimune's first quarter fiscal 2026 results, reported on August 7, 2025, reflected the financial strain of preparing for a commercial launch that has now been postponed. The company's net loss widened 61.2% to $86.7 million from $53.8 million in the same quarter of the previous fiscal year, with earnings per share coming in at $(0.95).
Research and development expenses surged 34.4% year-over-year to $57.8 million, driven by increased personnel, medical affairs spending, and consulting costs as the company prepared for the expected commercial launch. Selling, general, and administrative expenses more than doubled to $32.6 million from $14.4 million in Q1 FY2025, reflecting the completed build-out of customer-facing organization, commercial infrastructure, stock-based compensation expenses, and pre-launch activities.
Despite these substantial investments in commercial readiness—including hiring and training commercial teams, establishing distribution and reimbursement infrastructure, and manufacturing product inventory—the regulatory delay means these resources are not currently contributing to commercial returns.
Clinical Pipeline and Trial Progress
RP1 is an oncolytic immunotherapy that uses a modified virus to directly destroy tumor cells while stimulating anti-cancer immune responses. In clinical studies, including the ongoing ARTACUS trial for skin cancer (search) in organ transplant recipients, RP1 demonstrated a 34.6% overall response rate with a 24-month response duration observed in 61% of responders.
The company continues enrollment in the confirmatory IGNYTE-3 Phase 3 trial for RP1 in melanoma, which aims to enroll 400 patients globally. This study is specifically designed to collect data requested by regulators, including overall survival outcomes that may be critical for addressing the FDA's concerns outlined in the Complete Response Letter.
RP1 is being evaluated in combination with checkpoint inhibitors such as nivolumab, a Bristol Myers Squibb (search) therapy that blocks the PD-1 (search) pathway to enhance immune system response against cancer. This combination approach represents a key differentiating strategy for Replimune's oncolytic virus platform.
Broader Pipeline Development
Beyond RP1, Replimune continues advancing its pipeline with RP2, an oncolytic immunotherapy engineered for broader anti-tumor activity. Key ongoing studies include the REVEAL trial in metastatic uveal melanoma (search) and additional studies in hepatocellular and biliary tract cancers conducted in collaboration with Roche.
The company's strategic partnerships with major pharmaceutical companies, including Bristol Myers Squibb (search) and Roche, provide clinical support and validation for its oncolytic virus approach. However, the near-term outlook remains heavily dependent on regulatory outcomes for RP1.
Financial Position and Outlook
Replimune ended the quarter with $403.3 million in cash, cash equivalents, and short-term investments, representing a decrease of $80.5 million from Q4 FY2025. The company estimates its cash runway extends into the fourth quarter of FY2026, not accounting for potential product revenues or additional capital-raising events.
Management has not provided revenue guidance or projections for future quarters, citing ongoing uncertainty following the FDA's regulatory feedback on RP1. The company indicated it will provide updates on product launch metrics and revenues once there is clarity on regulatory resolution and product availability.
The regulatory setback highlights the challenges facing oncolytic immunotherapy development and the critical importance of successfully navigating FDA review processes for biotechnology companies seeking to differentiate their cancer immunotherapies in a competitive landscape.